Your browser doesn't support javascript.
loading
Vaccination coverage and adherence to a dengue vaccination program in the state of Paraná, Brazil.
Preto, Clara; Maron de Mello, Angela; Cesário Pereira Maluf, Eliane Mara; Teixeira Krainski, Elias; Graeff, Gabriel; de Sousa, Gabriela Amanda; da Silva, Lineu Roberto; Vieira da Costa-Ribeiro, Magda Clara; da Cruz Magalhães Buffon, Marilene; Shimakura, Silvia Emiko; Raboni, Sonia Mara; Siqueira de Carvalho, Denise; Luhm, Karin Regina.
Afiliação
  • Preto C; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil. Electronic address: clarampreto@hotmail.com.
  • Maron de Mello A; National Audit Department of Brazilian Public Health/Health Ministry, Rua Cândido Lopes, 208 - Centro, Curitiba, PR 80020-060, Brazil.
  • Cesário Pereira Maluf EM; Universidade Federal do Paraná (UFPR), Public Health Department, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Teixeira Krainski E; Universidade Federal do Paraná (UFPR), Statistics Department, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Graeff G; Fundação de Apoio da Universidade Federal do Paraná (FUNPAR), Rua João Negrão, 280 - Centro, Curitiba, PR 80010-200, Brazil.
  • de Sousa GA; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • da Silva LR; Universidade Federal do Paraná (UFPR), Public Health Department, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Vieira da Costa-Ribeiro MC; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • da Cruz Magalhães Buffon M; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Shimakura SE; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Raboni SM; Universidade Federal do Paraná (UFPR), Public Health Department, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Siqueira de Carvalho D; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
  • Luhm KR; Universidade Federal do Paraná (UFPR), Postgraduate Program in Public Health - Curitiba, Rua Padre Camargo, 280 - Alto da Glória, Curitiba, PR 80060-240, Brazil.
Vaccine ; 39(4): 711-719, 2021 01 22.
Article em En | MEDLINE | ID: mdl-33386178
The success of vaccination programs depends on the level of acceptance of the vaccine to achieve high vaccine coverage rates (VCR). Vaccine hesitancy is a challenge, especially concerning new vaccines. Dengue vaccine, Dengvaxia®, was licensed in Brazil in 2015 and implemented, in a pioneering publicly-funded initiative in the state of Paraná, between 2016 and 2018. The vaccination program took place in five phases in the 30 municipalities most affected by dengue in the state, targeting individuals from nine to 44 years-old in two cities and from 15 to 27 years-old in the other 28 municipalities, totaling a target population of 500,000 individuals. A cross-sectional descriptive study was carried out to assess VCR and adherence to the dengue vaccine in this program. VCR, dropout ratio (DR), and compliance with the vaccination schedule (CVS) were analyzed by sex, age group, and municipality size. A total of 302,603 individuals (60.5%) received ≥ 1 dose, 44.2% received ≥ 2 doses, and 28.6% 3 doses. The DR was 52.8%. Among individuals who started vaccination, 40.6% achieved CVS. The highest VCR, highest CVS, and lowest DR occurred in the age group from 9 to 14 years old and from 28 to 44 years old and in smaller municipalities. A greater proportion of men started vaccination (male 64.0%; female 57.1%) however, the DR was higher in men (male 55.4%; female 49.9%), and a higher percentage of women completed the vaccination schedule according to the recommendations (CVS male 37.8%; female 43.6%). Differences were noted in the CVS according to the initial phase of the program (first phase 50.8%; second phase 18.8%). The heterogeneity in vaccine uptake and compliance according to sex, age, and municipality size suggests the need for differentiated strategies to address challenges with new and multiple-dose vaccines.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dengue / Cobertura Vacinal Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Implementation_research Limite: Adolescent / Adult / Child / Female / Humans / Male País/Região como assunto: America do sul / Brasil Idioma: En Revista: Vaccine Ano de publicação: 2021 Tipo de documento: Article País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dengue / Cobertura Vacinal Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Implementation_research Limite: Adolescent / Adult / Child / Female / Humans / Male País/Região como assunto: America do sul / Brasil Idioma: En Revista: Vaccine Ano de publicação: 2021 Tipo de documento: Article País de publicação: Holanda